• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童噬血细胞性淋巴组织细胞增生症的诊断前轨迹:血液学和肝脏参数观察

Pre-diagnostic trajectory of pediatric hemophagocytic lymphohistiocytosis: observations from hematological and hepatic parameters.

作者信息

Li Xun, Yan Haipeng, Cai Zili, Li Xiao, Xie Longlong, Luo Ting, Wang Xiangyu, Yang Yufan, Gong Ling, Tang Minghui, Zhang Xinping, Huang Jiaotian, Lu Xiulan, Xiao Zhenghui

机构信息

Pediatrics Research Institute of Hunan Province, Affiliated Children's Hospital of Xiangya School of Medicine, Central South University (Hunan Children's Hospital), Changsha, China.

Pediatric Intensive Care Unit, Affiliated Children's Hospital of Xiangya School of Medicine, Central South University (Hunan Children's Hospital), Changsha, China.

出版信息

Ann Hematol. 2024 Dec;103(12):5145-5155. doi: 10.1007/s00277-024-06073-4. Epub 2024 Oct 27.

DOI:10.1007/s00277-024-06073-4
PMID:39463183
Abstract

Understanding the early features and characteristics of hemophagocytic lymphohistiocytosis (HLH) is essential for identifying high-risk individuals and also providing valuable pathological insights. This study aims to investigate the characteristics and trends of blood and hepatic parameters before an HLH diagnosis was established. Longitudinal hematological and hepatic test results from pediatric patients with HLH and an age- and sex-matched control group were analyzed. According to the length of time between hospital admission and the establishment of the HLH diagnosis, the HLH cases were divided into early-onset (≤ 7 days) and late-onset (> 7days) groups. Among the 229 pediatric HLH patients, the length of time between hospital admission and the establishment of an HLH diagnosis ranged from 0 to 41 days (median = 4 days). Over 80% of pediatric HLH patients presented abnormal laboratory results for aspartate aminotransferase (AST), triglycerides, lactate dehydrogenase (LDH), and hemoglobin at admission. The abnormal rates in the initial platelet count, neutrophil count, and fibrinogen tests were 67.3%, 48.3%, and 52.2%, respectively. The initial test results for AST, alanine aminotransferase (ALT), LDH, serum sodium, and albumin showed AUCs > 80% for discriminating early-onset HLH. For the discrimination of late-onset HLH, the performance of initial test results was poor. To conclude, abnormalities in AST, triglycerides, LDH, and hemoglobin are early presentations of pediatric HLH; platelet, neutrophil, and fibrinogen levels may become abnormal at a relatively late stage of the HLH disease trajectory; and the initial test results for AST, ALT, LDH, serum sodium, and albumin can be used to identify suspected early-onset HLH.

摘要

了解噬血细胞性淋巴组织细胞增生症(HLH)的早期特征对于识别高危个体以及提供有价值的病理见解至关重要。本研究旨在调查在HLH诊断确立之前血液和肝脏参数的特征及变化趋势。分析了HLH儿科患者以及年龄和性别匹配的对照组的纵向血液学和肝脏检查结果。根据入院至HLH诊断确立之间的时间长度,将HLH病例分为早发型(≤7天)和晚发型(>7天)组。在229例儿科HLH患者中,入院至HLH诊断确立的时间长度为0至41天(中位数=4天)。超过80%的儿科HLH患者入院时天门冬氨酸氨基转移酶(AST)、甘油三酯、乳酸脱氢酶(LDH)和血红蛋白的实验室检查结果异常。初始血小板计数、中性粒细胞计数和纤维蛋白原检查的异常率分别为67.3%、48.3%和52.2%。AST、丙氨酸氨基转移酶(ALT)、LDH、血清钠和白蛋白的初始检查结果在鉴别早发型HLH时的曲线下面积(AUC)>80%。对于晚发型HLH的鉴别,初始检查结果的表现较差。总之,AST、甘油三酯、LDH和血红蛋白异常是儿科HLH的早期表现;血小板、中性粒细胞和纤维蛋白原水平可能在HLH病程的相对晚期变得异常;AST、ALT、LDH、血清钠和白蛋白的初始检查结果可用于识别疑似早发型HLH。

相似文献

1
Pre-diagnostic trajectory of pediatric hemophagocytic lymphohistiocytosis: observations from hematological and hepatic parameters.儿童噬血细胞性淋巴组织细胞增生症的诊断前轨迹:血液学和肝脏参数观察
Ann Hematol. 2024 Dec;103(12):5145-5155. doi: 10.1007/s00277-024-06073-4. Epub 2024 Oct 27.
2
Secondary hemophagocytic lymphohistiocytosis in pediatric patients with visceral leishmaniasis and Epstein-Barr virus infection.儿童内脏利什曼病和 Epstein-Barr 病毒感染患者中的继发性噬血细胞性淋巴组织细胞增生症。
Ann Hematol. 2024 May;103(5):1541-1547. doi: 10.1007/s00277-024-05695-y. Epub 2024 Mar 12.
3
Clinical characteristics of hemophagocytic lymphohistiocytosis.噬血细胞性淋巴组织细胞增生症的临床特征。
Technol Health Care. 2024;32(4):2509-2526. doi: 10.3233/THC-231275.
4
Critical risk factors analysis of infection-associated hemophagocytic lymphohistiocytosis in children.儿童感染相关性噬血细胞性淋巴组织细胞增生症的关键危险因素分析
Ann Hematol. 2025 Jan;104(1):111-121. doi: 10.1007/s00277-024-06058-3. Epub 2024 Nov 4.
5
Study on ferritin and liver injury in pediatric hemophagocytic lymphohistiocytosis associated with infection.感染相关小儿噬血细胞性淋巴组织细胞增生症中铁蛋白与肝损伤的研究
Sci Rep. 2025 Apr 12;15(1):12662. doi: 10.1038/s41598-025-96533-2.
6
Clinical laboratory Analysis of EB Virus Associated Hemophagocytic Lymphohistiocytosis in Children.儿童 EB 病毒相关性噬血细胞性淋巴组织细胞增生症的临床实验室分析。
Altern Ther Health Med. 2024 May;30(5):148-154.
7
Diagnostic accuracy of bone marrow blood evaluation in haemophagocytic lymphohistiocytosis paediatric patients.
Ann Clin Biochem. 2025 Mar;62(2):91-100. doi: 10.1177/00045632241295694. Epub 2024 Oct 24.
8
Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis.噬血细胞性淋巴组织细胞增生症患儿炎症细胞因子与器官损害之间的关联。
Cytokine. 2016 Sep;85:14-7. doi: 10.1016/j.cyto.2016.05.022. Epub 2016 Jun 4.
9
Cytokine storm in severe COVID-19 pneumonia.重症 COVID-19 肺炎中的细胞因子风暴。
J Med Virol. 2021 Sep;93(9):5474-5480. doi: 10.1002/jmv.27068. Epub 2021 May 15.
10
Outcome analysis of pediatric hemophagocytic lymphohistiocytosis.小儿噬血细胞性淋巴组织细胞增生症的疗效分析。
J Formos Med Assoc. 2021 Jan;120(1 Pt 1):172-179. doi: 10.1016/j.jfma.2020.03.025. Epub 2020 Apr 16.

引用本文的文献

1
Optimizing hemophagocytic lymphohistiocytosis screening in children: validation of the HLH-Screen score.优化儿童噬血细胞性淋巴组织细胞增生症筛查:HLH-筛查评分的验证
Ann Hematol. 2025 Jun 20. doi: 10.1007/s00277-025-06465-0.

本文引用的文献

1
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.原发性噬血细胞性淋巴组织细胞增生症患者接受emapalumab 治疗的真实世界治疗模式和结局。
Blood Adv. 2024 May 14;8(9):2248-2258. doi: 10.1182/bloodadvances.2023012217.
2
A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults.一项评估透明质酸酶促进皮下免疫球蛋白 20%在健康成年人中的耐受性、安全性和免疫原性的 1 期开放性研究。
J Clin Immunol. 2023 Dec 22;44(1):28. doi: 10.1007/s10875-023-01632-2.
3
Ruxolitinib-based regimen in children with primary hemophagocytic lymphohistiocytosis.
基于鲁索利替尼的方案治疗原发性噬血细胞性淋巴组织细胞增生症患儿。
Haematologica. 2024 Feb 1;109(2):458-465. doi: 10.3324/haematol.2023.283478.
4
Sepsis subphenotyping based on organ dysfunction trajectory.基于器官功能轨迹的脓毒症亚表型分型。
Crit Care. 2022 Jul 3;26(1):197. doi: 10.1186/s13054-022-04071-4.
5
The prevalence and prognosis of hyponatraemia in non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis.非霍奇金淋巴瘤相关噬血细胞性淋巴组织细胞增生症中低钠血症的患病率和预后
Leuk Lymphoma. 2022 Feb;63(2):362-369. doi: 10.1080/10428194.2021.1992623. Epub 2021 Oct 18.
6
Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults.危重症儿童和成人噬血细胞性淋巴组织细胞增生症识别、诊断及管理的基于共识的指南
Crit Care Med. 2022 May 1;50(5):860-872. doi: 10.1097/CCM.0000000000005361. Epub 2021 Oct 5.
7
A Minimal Parameter Set Facilitating Early Decision-making in the Diagnosis of Hemophagocytic Lymphohistiocytosis.一个简化参数集,有助于在噬血细胞性淋巴组织细胞增生症的诊断中尽早做出决策。
J Clin Immunol. 2021 Aug;41(6):1219-1228. doi: 10.1007/s10875-021-01005-7. Epub 2021 Mar 29.
8
Biomarkers for Early Diagnosis of Hemophagocytic Lymphohistiocytosis in Critically Ill Patients.用于危重症患者噬血细胞性淋巴组织细胞增生症早期诊断的生物标志物。
J Clin Immunol. 2021 Apr;41(3):658-665. doi: 10.1007/s10875-020-00950-z. Epub 2021 Jan 8.
9
Clinical profiles and risk factors of 7-day and 30-day mortality among 160 pediatric patients with hemophagocytic lymphohistiocytosis.160 例噬血细胞性淋巴组织细胞增生症患儿 7 天和 30 天死亡率的临床特征和危险因素。
Orphanet J Rare Dis. 2020 Aug 31;15(1):229. doi: 10.1186/s13023-020-01515-4.
10
CD163 as a valuable diagnostic and prognostic biomarker of sepsis-associated hemophagocytic lymphohistiocytosis in critically ill children.CD163 作为一种有价值的诊断和预后生物标志物,可用于诊断危重症儿童感染相关性噬血细胞性淋巴组织细胞增多症。
Pediatr Blood Cancer. 2019 Oct;66(10):e27909. doi: 10.1002/pbc.27909. Epub 2019 Jul 12.